Astex selects PharmaVentures to assist in divesment of CMC & Formulation Facility

Sep 9 2011NewsGuard 100/100 Score

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, "We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders.  With 20 years' experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site."

Source:

Pharma Ventures Ltd

Posted in: Business / Finance | Pharmaceutical News

Tags: , ,

Comments (0)

Suggested Reading

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
New method accelerates drug discovery from years to months
TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies
Revolutionizing drug discovery with SmartCADD
New technology streamlines drug discovery using single-molecule tracking
Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery
The Key Role of iPSC-Derived Microglia in Research and Drug Discovery
KiNet web portal enhances study of kinase functions in cellular signaling pathways

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease